THOUSAND OAKS, Calif., July 30, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2015. Key results include:
•Total revenues increased 4 percent versus the second quarter of 2014 to $5,370 million, with 6 percent product sales growth driven primarily by Enbrel® (etanercept), Prolia® (denosumab), Sensipar® (cinacalcet), Kyprolis® (carfilzomib) and XGEVA® (denosumab). Unfavorable changes in foreign exchange rates impacted total revenue and product sales growth by approximately 2.5 percentage points.
•Adjusted EPS grew 8 percent versus the second quarter of 2014 to $2.57 driven by higher revenues and lower operating expenses. Adjusted operating income increased 10 percent to $2,551 million.
•Adjusted operating margin improved by approximately 2 percentage points to 49 percent.
•GAAP EPS were $2.15 compared to $2.01 and GAAP operating income was $2,076 million compared to $1,902 million.
•The Company generated $2.7 billion of free cash flow compared to $2.1 billion in the second quarter of 2014.
Help employers find you! Check out all the jobs and post your resume.
